Harpoon Therapeutics, Inc.(HARP)

Sector:

Healthcare

Description:

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Current Price

$0.80

RSI

72.13

Market Capitalization:

217.6M

Beta:

0.715

Volume:

691,453

Analyst Target Price:

$ 26.7

Economiic Fair Price:


November 09, 2022
November 14, 2022
Q3
N/A
N/A
N/A
N/A
N/A
50.4M
11M
-3.606
N/A
0.917
-1.267

7.86 %
1.01 %
0.04 %
203.68 %
30.22 %
-17.11 %

$ 23.7M
35.60 %
$ 17.4M
201.96 %
$ 5.8M
21.62 %
$ 4.8M
570.90 %
$ 708K

$ -122.3M
-1214.70 %
$ -9.3M
-45.14 %
$ -6.4M
76.94 %
$ -27.8M
-4853.48 %
$ -561K
95.06 %
$ -11.3M

$ -116.7M
-133.87 %
$ -49.9M
10.19 %
$ -55.6M
-103.07 %
$ -27.4M
-62.60 %
$ -16.8M

News

Press Releases

Notable Dates